Zephyr AI Raises $111 Million in Series A Financing
Summary
The company is developing improved data federation tools along with various machine learning algorithms in the areas of oncology and cardiometabolic disease.The US has the highest rate of avoidable cancer and cardiometabolic-related deaths among any high-income country. Collectively, we are now well positioned to support our mission of democratizing precision medicine, enhancing both the speed and success of clinical trials.According to Dr. Justin Stebbing, Chairman of Zephyr AIs Scientific and Medical Advisory Board, Editor of Oncogene (published under the Nature portfolio), and Professor of Biomedical Sciences at ARU, Cambridge, the companys technology stands out along two crucial dimensions. "The expansion of our diverse multimodal data resources will accelerate the advancement of Zephyr AIs algorithms, paving the way for us to transform the landscape of precision medicine and improve outcomes for our partners and patients, said Jeff Sherman, Co-Founder, Interim CEO, and Chief Technology Officer of Zephyr AI.Zephyr AI has had two abstracts accepted for publication at the American Association for Cancer Research (AACR) annual meeting to be held in San Diego on April 5-10, 2024.We are excited to be part of this growing ecosystem of AI-enabled drug development and welcome the opportunity to attend AACR where we will engage with the scientific community and present some of our emerging scientific insights from our platform, Sherman said.Zephyr AI is a high-growth healthcare technology company committed to radically reshaping precision medicine in oncology and cardiometabolic disease. Through partnerships and proprietary data, Zephyr AI is curating the worlds most comprehensive healthcare dataset and marrying it with cutting-edge artificial intelligence algorithms to generate novel, translatable insights to build tools and products that support patients and providers and fuel ongoing research. At Zephyr AI, our mission-focused team of world-class software engineers and biologists leverage big data and next-generation technology to derive transformational insights and build enduring partnerships that will revolutionize the treatment of cancer and cardiometabolic disease.